Endo Pharma (ENDP) Posts Q3 EPS of $0.63, Misses By 1c; Guides
More News related to ENDP
- Endo Pharma (ENDP) Announces Settlement with LecTec Over Outstanding Patent Litigation
- Endo Pharmaceuticals and LecTec Settle Patent Dispute
- Endo Pharma (ENDP) Posts Q3 EPS of $0.63, Misses By 1c; Guides
- Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
Endo Pharmaceuticals (NASDAQ: ENDP) reports Q3 EPS of $0.63, versus the analyst estimate of $0.64. Revenue for the quarter was $361.03 million, which compares to the estimate of $365.33 million.
Raises FY09 Guidance to $1.44 - $1.465 billion., and FY09 adjusted EPS expected to be $2.67 - $2.73.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.29Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
